These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 7329211)

  • 1. Hypolipidemic effects of clofibrate and selected chroman analogs in fasted rats: I. Chow-fed animals.
    O'Brien M; Patel ST; Mukhopadhyay A; Newman HA; Feller DR; Kokrady SS; Witiak DT; Lanese RR; Rice JC
    Lipids; 1981 Dec; 16(12):903-11. PubMed ID: 7329211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypolipidemic effects of clofibrate and selected chroman analogs in fasted rats: II. High sucrose-fed animals.
    Mukhopadhyay A; Patel ST; O'Brien M; Kokrady SS; Newman HA; Witiak DT; Lanese RR; Rice JC; Feller DR
    Lipids; 1983 Jan; 18(1):59-67. PubMed ID: 6835036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antilipidemic activity of 4-oxo-functionalized ethyl 6-chlorochroman-2-carboxylate analogs and a related tricyclic lactone in three rat models.
    Cavestri RC; Minatelli JA; Baldwin JR; Loh W; Feller DR; Newman HA; Sober CL; Witiak DT
    Lipids; 1981 Jan; 16(1):30-6. PubMed ID: 7219078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alterations in rat serum lipids and apolipoproteins following clofibrate treatment.
    Dashti N; Ontko JA
    Atherosclerosis; 1983 Dec; 49(3):255-66. PubMed ID: 6419747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of KC-9432, a new hypolipidemic compound, on high density lipoprotein cholesterol in rats.
    Seri K; Sato R; Hamazaki Y; Yamamoto T; Ishiyama N
    Atherosclerosis; 1980 Sep; 37(1):97-102. PubMed ID: 6893550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential effects of benzodioxane, chroman and dihydrobenzofuran analogs of clofibrate in a Triton hyperlipemic rat model.
    Newman HA; Heilman WP; Witiak DT
    Lipids; 1973 Jul; 8(7):378-84. PubMed ID: 4724016
    [No Abstract]   [Full Text] [Related]  

  • 7. Influence of clofibrate on plasma lecithin: cholesterol acyltransferase (LCAT) activity in rats.
    Cisternas JR
    Rev Bras Pesqui Med Biol; 1979 Sep; 12(4-5):317-24. PubMed ID: 531275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of hypocholesterolemic activity for cyclic analogs of clofibrate in normolipemic rats.
    Goldberg AP; Mellon WS; Witiak DT; Feller DR
    Atherosclerosis; 1977 May; 27(1):15-25. PubMed ID: 857813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Action of clofibrate and its analogs in rats. Dissociation of hypolipidemic effects and the induction of peroxisomal beta-oxidation.
    Harrison EH
    Biochim Biophys Acta; 1984 Nov; 796(2):163-8. PubMed ID: 6541949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aminophenyl ether compound (YM-95831), a new hypolipidemic agent with a high density lipoprotein elevating activity in rats.
    Ohata I; Sakamoto N; Nitatori R; Maeno H
    Arzneimittelforschung; 1983; 33(2):237-41. PubMed ID: 6682662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum lipoprotein and apoprotein concentrations in 4-(4-chlorophenyl)-2-hydroxytetronic acid and clofibrate-treated cholesterol and cholic acid-fed rats.
    Kamanna VS; Newman HA; Patel ST; Tehim AK; Witiak DT; Feller DR
    Lipids; 1989 Jan; 24(1):25-32. PubMed ID: 2747427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The lipid-lowering profile in rodents. AZ-1355, a new dibenzoxazepine derivative.
    Wada S; Koizumi M; Sasahara K; Neichi T; Nakakimura H; Onoda F; Hata SI
    Atherosclerosis; 1981; 40(3-4):263-71. PubMed ID: 7332605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of bezafibrate on plasma lipids, lipoproteins, apolipoproteins AI, AII and B and LCAT activity in hyperlipidemic, non-insulin-dependent diabetics.
    Prager R; Schernthaner G; Kostner GM; Mühlhauser I; Zechner R; Dorda W
    Atherosclerosis; 1982 Jun; 43(2-3):321-7. PubMed ID: 6810904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protective effect of rutin on lipids, lipoproteins, lipid metabolizing enzymes and glycoproteins in streptozotocin-induced diabetic rats.
    Stanely Mainzen Prince P; Kannan NK
    J Pharm Pharmacol; 2006 Oct; 58(10):1373-83. PubMed ID: 17034661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clofibrate decreases jejunal cholesterol synthesis and activity of postheparin plasma lipoprotein lipase in the rat.
    Strandberg TE; Kuusi T; Tilvis RS; Miettinen TA
    Pharmacology; 1983; 26(5):290-6. PubMed ID: 6856670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypolipidemic effect of ethyl all-cis-5,8,11,14,17-eicosapentaenoate (EPA-E) in rats.
    Mizuguchi K; Yano T; Kojima M; Tanaka Y; Ishibashi M; Masada A; Sato M; Mizota M; Fukutake K; Saito Y
    Jpn J Pharmacol; 1992 Jul; 59(3):307-12. PubMed ID: 1434127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of clofibrate, bezafibrate, fenofibrate and probucol on plasma lipolytic enzymes in normolipaemic subjects.
    Heller F; Harvengt C
    Eur J Clin Pharmacol; 1983; 25(1):57-63. PubMed ID: 6617725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis of ethyl 6-substituted-chroman- and -chromone-2-carboxylates. A comparative structure-activity study employing the 6-phenyl and phenoxy analogs in the triton hyperlipidemic rat model.
    Witiak DT; Heilman WP; Sankarappa SK; Cavestri RC; Newman HA
    J Med Chem; 1975 Sep; 18(9):935-42. PubMed ID: 1159716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low density lipoprotein-lowering and high density lipoprotein-elevating effects of nicardipine in rats.
    Ohata I; Sakamoto N; Nagano K; Maeno H
    Biochem Pharmacol; 1984 Jul; 33(14):2199-205. PubMed ID: 6466343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum lipoprotein lipids after gemfibrozil treatment.
    Schwandt P; Weisweiler P; Neureuther G
    Artery; 1979 Feb; 5(2):117-24. PubMed ID: 231950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.